A large proportion of prediabetes and diabetes goes undiagnosed when only fasting plasma glucose and/or HbA1c are measured in overweight or obese patients;Proportion considérable de prédiabète et de diabète méconnus par la glycémie à jeun ou l'HbA1c seule chez des patients en surpoids ou obèses

Diabetes and Metabolism

Volumn 36, Issue 4, 2010, Pages 312-318

  Cosson, E ^a,b   Hamo Tchatchouang, E ^a   Banu, I ^a   Nguyen, M T ^a,b   Chiheb, S ^a   Ba, H ^a   Valensi, P ^a  

^a HÔPITAL JEAN VERDIER   (France)

^b UNIVERSITÉ PARIS 13   (France)

Author keywords

French National Agency of Accreditation and Evaluation in Health Care (ANAES); HbA1c; Obesity; Oral glucose tolerance test; Overweight; Prediabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLUCOSE; HEMOGLOBIN A1C;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC VALUE; DIET RESTRICTION; DYSLIPIDEMIA; FEMALE; FRANCE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC INDEX; HEALTH CARE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; HYPERTENSION; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; WAIST CIRCUMFERENCE;

ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; COMORBIDITY; DIABETES MELLITUS; FASTING; FEMALE; FRANCE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PREDIABETIC STATE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; WAIST CIRCUMFERENCE;

EID: 77956966285     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.02.004     Document Type: Article

References (29)

1. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31(suppl. 1):S55-60.
3. Alberti K.G., Zimmet P., Shaw J. International diabetes federation: a consensus on type 2 diabetes prevention. Diabet Med 2007, 24:451-463.
4. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
5. Lindstrom J., Ilanne-Parikka P., Peltonen M., Aunola S., Eriksson J.G., Hemio K., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish diabetes prevention study. Lancet 2006, 368:1673-1679.
6. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077.
7. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
8. Gerstein H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105.
9. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
10. Agence nationale d'accréditation et d'évaluation en santé. Principes de dépistage du diabète de type 2. Report 2003.
11. ADA. Clinical practice recommendations 2008. Diabetes Care 2008;31:S1-110.
12. Ryden L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.J., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007, 28:88-136.
13. Santaguida P.L., Balion C., Hunt D., Morrison K., Gerstein H., Raina P., et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summ) 2005, 1-11.
14. Gerstein H.C., Santaguida P., Raina P., Morrison K.M., Balion C., Hunt D., et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007, 78:305-312.
15. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hr diagnostic criteria. Arch Intern Med 2001;161:397-404.
16. Balkau B., Eschwege E. Epidemiological data on postprandial glycaemia. Diabetes Metab 2006, 32(Spec No2:2):S5-S9.
17. Barr E.L., Zimmet P.Z., Welborn T.A., Jolley D., Magliano D.J., Dunstan D.W., et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian diabetes, obesity, and lifestyle study (AusDiab). Circulation 2007, 116:151-157.
18. Cowie C.C., Rust K.F., Ford E.S., Eberhardt M.S., Byrd-Holt D.D., Li C., et al. Full accounting of diabetes and pre-diabetes in the U.S. Population in 1988-1994 and 2005-2006. Diabetes Care 2009, 32:287-294.
19. The DECODE study group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003;26:61-9.
20. Edelman D., Olsen M.K., Dudley T.K., Harris A.C., Oddone E.Z. Utility of hemoglobin A1c in predicting diabetes risk. J Gen Intern Med 2004, 19:1175-1180.
21. Droumaguet C., Balkau B., Simon D., Caces E., Tichet J., Charles M.A., et al. Use of HbA1c in predicting progression to diabetes in French men and women: data from an epidemiological study on the insulin resistance syndrome (DESIR). Diabetes Care 2006, 29:1619-1625.
22. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34.
23. Wilkerson H.L., Hyman H., Kaufman M., Mc C.A., Francis J.O. Diagnostic evaluation of oral glucose tolerance tests in nondiabetic subjects after various levels of carbohydrate intake. N Engl J Med 1960, 262:1047-1053.
24. Genuth S., Alberti K.G., Bennett P., Buse J., Defronzo R., Kahn R., et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26:3160-3167.
25. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
26. Valensi P., Schwarz E.H., Hall M., Felton A.M., Maldonato A., Mathieu C. Pre-diabetes essential action: a European perspective. Diabetes Metab 2005, 31:606-620.
27. Balion C.M., Raina P.S., Gerstein H.C., Santaguida P.L., Morrison K.M., Booker L., et al. Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review. Clin Chem Lab Med 2007, 45:1180-1185.
28. Trell E., Kristenson H., Peterson B., Fex G., Henningsen N.C., Berntorp K., et al. Two-hour glucose and insulin responses after a standardized oral glucose load in relation to serum gamma-glutamyl transferase and alcohol consumption. Acta Diabetol Lat 1981, 18:311-317.
29. Fraser A., Harris R., Sattar N., Ebrahim S., Davey Smith G., Lawlor D.A. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British women's heart and health study and meta-analysis. Diabetes Care 2009, 32:741-750.